Wallace Peggy 4

What Happened
Peggy Wallace, a director of Cognition Therapeutics, was granted 25,000 restricted stock units (RSUs) on June 17, 2026. The RSUs were awarded at an acquisition price of $0.00, so no cash was exchanged; the filing reports an acquisition of 25,000 units (total immediate cash value $0). This is an equity award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-17; Filing date (SEC accession): 2026-06-22 (appears later than the typical 2-business-day Form 4 deadline).
• Instrument and amount: 25,000 RSUs granted (transaction code A — Award/Grant). Reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnote (from filing): Each RSU is a contingent right to one share upon settlement. RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the reporting person’s continuous service as a director.
• This award appears to be routine director compensation rather than a purchase (bullish signal) or a sale.

Context
RSUs do not represent immediate ownership of shares until they vest and are settled; they generally do not convey voting rights or liquidity until converted to common stock. The economic value will depend on CGTX’s share price at settlement. Director awards are common as part of compensation plans and should be viewed differently from open-market purchases or insider sales.